Claims for Patent: 11,583,643

Summary for Patent: 11,583,643

Title:	Inhalers and related methods
Abstract:	An inhaler (10) for the inhalation of inhalable substances comprise: a canister (50) having an interior reservoir (84) containing pressurised inhalable substances including fluid; a metering valve (52) including a metering chamber (82) and a valve stem (54) defining a communication path between the metering chamber and the interior reservoir, the communication path (86) including an opening (106) configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas such as air located within the metering chamber is replaced with liquid from the interior reservoir.
Inventor(s):	Daniel Buck, Paul Prendergast, Declan Walsh
Assignee:	Norton Waterford Ltd
Application Number:	US15/881,372
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,583,643
Patent Claims:	1. A method of metering inhalable substances, the method comprising: providing a medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir; operating the medicament inhaler to cause substances within the metering chamber to vaporise and the valve stem to be in a retracted position relative to the canister for a time period of about 2 minutes to about 24 hours such that atmospheric air enters the metering chamber; following the time period, orienting the interior reservoir above the metering chamber to permit the atmospheric air within the metering chamber to be replaced with a liquid replacement from the interior reservoir; and administering, from the liquid replacement, 75% to 125% of labelled claim for a dose. 2. The method of claim 1, in which the opening is configured to permit flow in a direction with an axial component along the valve stem directly between the transfer space inside the valve stem and the interior reservoir. 3. The method of claim 1 in which permitting the atmospheric air located in the metering chamber to be replaced with the liquid replacement from the interior reservoir includes flowing liquid under pressure through the opening, along the valve stem to a portion of the communication path communicating with the metering chamber. 4. The method of claim 1 including flowing gas from the metering chamber, in a direction counter to a direction of liquid flow from the interior reservoir, along the communication path into the interior chamber. 5. The method of claim 1 including providing the opening as an elongated opening. 6. The method of 5 including providing a second opening to the communication path diametrically opposed to the opening. 7. The method of claim 1 comprising providing the valve stem with said opening into the interior reservoir as having an axially oriented opening portion which is oriented facing directly axially along a longitudinal axis of the valve stem into the interior reservoir, and which includes flowing liquid into the metering chamber via said axially oriented opening portion. 8. The method of claim 1 comprising providing the medicament inhaler as a breath actuated inhaler, and which includes, in response to air flow, firing the canister by closing communication between the metering chamber and interior reservoir and opening communication between the metering chamber and atmosphere, the valve stem being held depressed after firing. 9. The method of claim 8 comprising resetting the inhaler to a reset configuration with a reset actuator so as to close communication between the metering chamber and atmosphere and open communication between the metering chamber and the interior reservoir, and by carrying out the orienting of the interior reservoir above the metering chamber while the inhaler is in the reset configuration. 10. The method of claim 9 comprising providing the reset actuator as dust cap or a mouthpiece cap for the inhaler and in which closing the cap resets the inhaler. 11. The method of claim 1 comprising providing the medicament inhaler as a metered dose inhaler and which includes applying a force to the canister to hold the valve stem depressed; and which includes subsequently releasing the canister to extend the valve stem and carrying out the orienting of the interior reservoir above the metering chamber. 12. The method of claim 1 including providing the inhalable substances as including at least one propellant. 13. The method of claim 12 including providing at least one said propellant as a hydrofluoroalkane. 14. The method of claim 1 including providing at least one propellant with a surface tension at 25° C. of about 6 to 10 mN/m, typically about 7 to 9 mN/m, about 8 mN/m being one example. 15. The method of claim 1 including providing the inhalable substances as including an active ingredient in suspension or in solution. 16. A method of treating a respiratory disease or disorder to administer a therapeutically effective amount of one or more active ingredients, the method including carrying out the method of claim 1. 17. The method of claim 16, wherein the inhaler is a breath-actuated inhaler and the step of actuating the inhaler comprises inhaling through the inhaler. 18. The method of claim 16, wherein the respiratory disease or disorder is asthma. 19. The method of claim 16, wherein the respiratory disease or disorder is COPD. 20. The method of claim 16, wherein the one or more active ingredients comprise a corticosteroid. 21. The method of claim 16, wherein the one or more active ingredients comprise beclomethasone dipropionate or tiotropium bromide. 22. The method of claim 1, including venting the metering chamber to atmosphere for a time period which is one hour, more than one hour, 24 hours or more than 24 hours. 23. The method of claim 16, wherein the inhaler comprises: a canister having an interior reservoir containing pressurized inhalable substances including fluid and atmospheric air; a metering valve including a metering chamber and a valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for an orientation above the metering chamber whereby gas located within the metering chamber is replaceable with liquid from the interior reservoir, wherein the method includes; leaving the metering chamber exposed to the atmosphere so as to permit substances within the metering chamber to vaporize and to permit atmospheric air to enter the metering chamber; turning the inhaler upright with respect to gravity and allowing the canister to extend to a rest position in which the metering chamber communicates with the interior reservoir such that any atmospheric air which has entered the metering chamber is expelled up into the interior reservoir of the canister; and administering a next dose without priming. 24. The method of claim 23, wherein the step of venting the metering chamber to the atmosphere to permit atmospheric air to enter the metering chamber is for a time period which is two minutes or more, one hour, more than one hour, 24 hours or more than 24 hours. 25. The method of claim 24, including administering 75% to 125% of labelled claim for a dose following venting the metering chamber to atmosphere. 26. The method of claim 1, wherein 75% to about 110% of the labelled claim for the dose is administered. 27. The method of claim 1, wherein the medicament inhaler includes a mouthpiece and a mouthpiece cap coupled to the mouthpiece, the mouthpiece cap having an open position and closed position, and the mouthpiece cap remaining in the open position from a start of the time period to an end of the time period. 28. The method of claim 27, wherein moving the mouthpiece cap from the open position to the closed position causes the valve stem to move from the retracted position to an extended position, the extended position allowing for communication between the metering chamber and interior reservoir. 29. The method of claim 1, wherein orienting the interior reservoir above the metering chamber causes the liquid replacement in the interior reservoir to travel through the opening into the metering chamber. 30. The method of claim 29, wherein orienting the interior reservoir above the metering chamber causes atmospheric air to travel through the opening into the interior reservoir. 31. The method of claim 1, wherein the time period is from about 5 minutes to about 24 hours. 32. The method of claim 1, wherein the time period is from about 30 minutes to about 24 hours. 33. The method of claim 1, wherein the opening includes an axially oriented opening portion oriented to face axially along a longitudinal axis of the valve stem into the interior reservoir. 34. The method of claim 1, wherein orienting the interior reservoir above the metering chamber causes the valves stem to reposition from the retracted position to an extended position. 35. A method of metering an inhalable composition comprising: discharging a first metered dose from a medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, configured to permit flow between the valve stem and the interior reservoir; upon discharge of the first metered dose, causing the valve stem to be in a retracted position for a time period of about 2 minutes to about 24 hours during which the metering chamber stays open and exposed to atmosphere to permit atmospheric air to enter the metering chamber; at an end of the time period, orienting the interior reservoir above the metering chamber to replace the atmospheric air within the metering chamber with a replacement liquid; and actuating the medicament inhaler to discharge a second metered dose having 75% to 125% of labelled claim for a dose from the replacement liquid. 36. A method of treating a respiratory disease or disorder by administering a therapeutically effective amount of one or more active ingredients, the method comprising: providing a breath-actuated medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir; operating the breath-actuated medicament inhaler to cause substances within the metering chamber to vaporise and the valve stem to be in a retracted position relative to the canister for a time period of about 2 minutes to about 24 hours such that atmospheric air enters the metering chamber, wherein operating the breath-actuated medicament inhaler includes inhaling through the breath-actuated medicament inhaler; following the time period, resetting the inhaler to a reset configuration with a reset actuator to close communication between the metering chamber and atmosphere and open communication between the metering chamber and the interior reservoir; while the inhaler is in the reset configuration, orienting the interior reservoir above the metering chamber to cause the atmospheric air within the metering chamber to be replaced with a liquid replacement from the interior reservoir; and administering, from the liquid replacement, 75% to 125% of labelled claim for a dose, wherein the respiratory disease includes one or more of asthma and COPD, and the one or more active ingredients include one or more of corticosteroid, beclomethasone dipropionate, and tiotropium bromide. 37. A method of treating a respiratory disease or disorder by administering a therapeutically effective amount of one or more active ingredients, the method comprising: providing a breath-actuated medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir; operating the breath-actuated medicament inhaler to cause substances within the metering chamber to vaporise and the valve stem to be in a retracted position relative to the canister for a time period of about 2 minutes to about 24 hours such that atmospheric air enters the metering chamber, wherein operating the breath-actuated medicament inhaler includes inhaling through the breath-actuated medicament inhaler; following the time period, resetting the inhaler to a reset configuration with a reset actuator to close communication between the metering chamber and atmosphere and open communication between the metering chamber and the interior reservoir; while the inhaler is in the reset configuration, orienting the interior reservoir above the metering chamber to cause the atmospheric air within the metering chamber to be replaced with a liquid replacement from the interior reservoir; and administering, from the liquid replacement, 75% to 125% of labelled claim for a dose, wherein the respiratory disease includes asthma, and the one or more active ingredients include corticosteroid. 38. A method of treating a respiratory disease or disorder by administering a therapeutically effective amount of one or more active ingredients, the method comprising: providing a breath-actuated medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir; operating the breath-actuated medicament inhaler to cause substances within the metering chamber to vaporise and the valve stem to be in a retracted position relative to the canister for a time period of about 2 minutes to about 24 hours such that atmospheric air enters the metering chamber, wherein operating the breath-actuated medicament inhaler includes inhaling through the breath-actuated medicament inhaler; following the time period, resetting the inhaler to a reset configuration with a reset actuator to close communication between the metering chamber and atmosphere and open communication between the metering chamber and the interior reservoir; while the inhaler is in the reset configuration, orienting the interior reservoir above the metering chamber to cause the atmospheric air within the metering chamber to be replaced with a liquid replacement from the interior reservoir; and administering, from the liquid replacement, 75% to 125% of labelled claim for a dose, wherein the respiratory disease includes asthma and the one or more active ingredients include beclomethasone dipropionate or tiotropium bromide. 39. A method of treating a respiratory disease or disorder by administering a therapeutically effective amount of one or more active ingredients, the method comprising: providing a breath-actuated medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir; operating the breath-actuated medicament inhaler to cause substances within the metering chamber to vaporise and the valve stem to be in a retracted position relative to the canister for a time period of about 2 minutes to about 24 hours such that atmospheric air enters the metering chamber, wherein operating the breath-actuated medicament inhaler includes inhaling through the breath-actuated medicament inhaler; following the time period, resetting the inhaler to a reset configuration with a reset actuator to close communication between the metering chamber and atmosphere and open communication between the metering chamber and the interior reservoir; while the inhaler is in the reset configuration, orienting the interior reservoir above the metering chamber to cause the atmospheric air within the metering chamber to be replaced with a liquid replacement from the interior reservoir; and administering, from the liquid replacement, 75% to 125% of labelled claim for a dose, wherein the respiratory disease includes COPD and the one or more active ingredients include corticosteroid. 40. A method of treating a respiratory disease or disorder by administering a therapeutically effective amount of one or more active ingredients, the method comprising: providing a breath-actuated medicament inhaler having a metering valve with a metering chamber and a valve stem extending from the metering chamber to an interior reservoir of a canister, the valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir; operating the breath-actuated medicament inhaler to cause substances within the metering chamber to vaporise and the valve stem to be in a retracted position relative to the canister for a time period of about 2 minutes to about 24 hours such that atmospheric air enters the metering chamber, wherein operating the breath-actuated medicament inhaler includes inhaling through the breath-actuated medicament inhaler; following the time period, resetting the inhaler to a reset configuration with a reset actuator to close communication between the metering chamber and atmosphere and open communication between the metering chamber and the interior reservoir; while the inhaler is in the reset configuration, orienting the interior reservoir above the metering chamber to cause the atmospheric air within the metering chamber to be replaced with a liquid replacement from the interior reservoir; and administering, from the liquid replacement, 75% to 125% of labelled claim for a dose, wherein the respiratory disease includes COPD and the one or more active ingredients include beclomethasone dipropionate or tiotropium bromide.